Akero Therapeutics (AKRO) Tops Q2 EPS by 1c

Akero Therapeutics (NASDAQ: AKRO) reported Q2 EPS of ($0.60), $0.01 better than the analyst estimate of ($0.61).

For earnings history and earnings-related data on Akero Therapeutics (AKRO) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Nike names former Pfizer CFO David Denton as new finance chief